Clene (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024

May 28, 2024 09:41:34
  • Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference
  • CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization
  • The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently participated in three investor conferences during May – The Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. These conferences provided Clene with the opportunity to present its lead drug candidate CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization.

The Mizuho Neuroscience Summit 2024 took take place on May 20-21 at the Boston Harbor Hotel in Boston, MA (https://ibn.fm/yVw8Y). This event, organized by Mizuho Americas, is part of their initiative to explore promising investment trends and breakthroughs in the field of…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]